1. Novel Agents in Multiple Myeloma The Pharmacist's View on Therapy

2. Learning Objectives

3. Patient Case MB

4. Elotuzumab Background

5. ELOQUENT-2 Study Design Len/Dex ± Elotuzumab

6. ELOQUENT-2 Efficacy

7. ELOQUENT-2 Safety

8. Patient Case JP

9. Ixazomib Drug Interactions

10. Ixazomib

11. TOURMALINE-MM1 Ixazomib + Len/Dex vs Placebo + Len/Dex

12. TOURMALINE-MM1 Efficacy

13. TOURMALINE-MM1 Toxicity

14. Ixazomib Pharmacist Perspective

15. Other Ixazomib Combinations

16. Patient Case (cont) JP

17. Daratumumab

18. Daratumumab Combination Therapy

19. Current and Future Place in Therapy

20. Therapies in Development Antibodies

21. Pembrolizumab + Pom/Dex

22. Pembrolizumab + Pom/Dex Safety and Tolerability

23. Therapies in Development

24. Questions and Answers

25. Abbreviations

26. Abbreviations (cont)

27. Abbreviations (cont)

28. Abbreviations (cont)